Carrick Therapeutics
is an Ireland-based biopharmaceutical company that researches and develops novel therapies for the treatment of cancer... Read moreCarrick Therapeutics
is an Ireland-based biopharmaceutical company that researches and develops novel therapies for the treatment of cancer... Read more
News
Dec 10, 2025
FinanzNachrichten
Carrick Therapeutics: CARRICK THERAPEUTICS LIMITED: Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer
May 15, 2025
FinanzNachrichten
Carrick Therapeutics: CARRICK THERAPEUTICS LIMITED: Carrick Therapeutics Announces New Clinical Data Supporting Biomarker-driven Patient Selection for Samuraciclib (CDK7i) in Combination with SERDs in Hormone Receptor Positive Advanced Breast Cancer
Dec 31, 2024
Pharamceutical Technology
Carrick Therapeutics: CT-7439 by Carrick Therapeutics for Breast Cancer: Likelihood of Approval
Sep 23, 2024
FinanzNachrichten
Carrick Therapeutics: CARRICK THERAPEUTICS LIMITED: Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)
Jun 05, 2024
FinanzNachrichten
Carrick Therapeutics: CARRICK THERAPEUTICS LIMITED: Carrick Therapeutics Establishes New Headquarters in Boston, Massachusetts
Jun 05, 2024
The Business Journals
Carrick Therapeutics: Dublin biotech relocates HQ to Boston
Feb 14, 2024
FinanzNachrichten
Carrick Therapeutics: CARRICK THERAPEUTICS LIMITED: Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
Dec 16, 2023
Life Care News
Carrick Therapeutics: Carrick Therapeutics Announces First Patient Dosed in Phase
Oct 18, 2023
FinanzNachrichten
Carrick Therapeutics: CARRICK THERAPEUTICS LIMITED; The Menarini Group: Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination with Elacestrant in Patients with Advanced Breast Cancer
Sep 07, 2023
FinanzNachrichten
Carrick Therapeutics: CARRICK THERAPEUTICS LIMITED: Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13
Carrick Therapeutics Competitors
1
2
3
4
5
6
7
8
9
10